Table 1.
Sunitinib | Bevacizumab | |
---|---|---|
N | 17 | 8 |
Male/female | 10/7 | 5/3 |
Mean age in years (range) | 59 (42–73) | 57 (47–70) |
RCC | 17 | 0 |
NSCLC | 0 | 8 |
Mean platelet count pretreatment * 109 (range) | 359 (49–930) | 212 (106–324) |
Bleeding event | 8 | – |
Grade one | 6 | – |
Grade three | 1 | – |
Grade four | 1 | – |
Renal cell cancer (RCC), non-small cell lung carcinoma (NSCLC)
N is the number of patients